$Novo Nordisk AS(NVO.US)
Context: Novo Nordisk has peaked around 148 and was on a downtrend since then. The company has unveiled ambitious pipeline plans, projecting $23 Billions in pipeline revenue by 2035 and yet shares slid 6% at one point during pre market today.
My trade: I bought in tranches all the way to $51 range during pullbacks, before closing out all my position at $59.35
Takeaway: Averaging into pullbacks during a broader post peak phase requires a plan and risk management as prices may or may not recover after that.
Good to determine if the stock fits into one's portfolio for investment or just for trading before buying into the stock.

